

1. (Currently amended) A delivery system for enabling the dispensing of medicinal foam producing compositions directly to an internal site in a human body, said delivery system comprising:

- A. a container constructed for receiving and retaining the medicinal foam producing compositions therein and incorporating an exit portal;
- B. closure means mounted to the portal of the container for securely retaining the medicinal composition; ~~and~~
- C. a medicinal foam producing composition comprising
  - a. between about 5% and 70% by weight based upon the weight composition of at least one surfactant selected from the group consisting of polysorbate 20, cocoamide DEA, polysorbate 60, polysorbate 80, ammonium or alkaline salts of sulfated aliphatic alcohols, ammonium or alkaline salts of sulfated aliphatic ethoxylated alcohols, cocoamido derivatives and ethoxylate aliphatic phenolics;
  - b. an effective amount of at least one therapeutic agent selected from the group consisting of antiseptic agents, anti-bacterial agents, anti-microbial agents, anti-viral agents, medicines, anti-inflammatory agents, analgesics, anesthetics, and anti-itch agents; and
  - c. water forming the balance; and

A<sub>1</sub>


D. a delivery nozzle or cannula mounted to the closure means and comprising:

- a. an elongated tube portion having an overall length constructed for ease of insertion into an orifice communicating with a cavity of the human body, said overall length being constructed to assure the complete insertion of the tube portion into the cavity without injuring any surrounding tissue; and
- b. at least one aperture formed along the distal end of said elongated tube portion for enabling the medicinal foam composition to be dispensed from the container through the tube portion directly to the desired site.

2. (Original) The delivery system defined in Claim 1, wherein said delivery nozzle or cannula further comprises an enlarged surface formed adjacent the proximal end thereof, for providing a positive stop for said tube member in order to prevent over-insertion of said tube member into the cavity.

3. (Original) The delivery system and defined in Claim 2, wherein said elongated tube portion is further defined as being formed from flexible material in order to assure ease of use and insertion thereof into the human body for being positioned in the precisely desired location.

4. (Original) The delivery system defined in Claim 2, wherein said closure means is further defined as comprising one selected from the group consisting of caps and finger-operated dispensing valves, and the delivery nozzle/cannula is further defined as being securely affixed to said closure means in a manner which prevents dislodgement thereof from said closure means.

 5. (Original) The delivery system defined in Claim 4, wherein the elongated tube portion of the delivery nozzle/cannula is further defined as comprising a tapered outer surface with a smaller diameter section being formed at the distal end thereof for further assisting in providing ease of insertion and positioning of the tube member in the desired orifice.

6. (Original) The delivery system defined in Claim 4, wherein the elongated tube portion of the delivery nozzle/cannula is further defined as comprising a substantially uniform diameter throughout the entire length thereof, with the distal end of said tube portion being smoothly rounded to assure ease of insertion into the desired orifice without injuring any surrounding tissue.

7. (Currently Amended) The delivery system defined in Claim 2, wherein said container is further defined as comprising a thin walled, flexible construction and said closure means comprises a cap member affixed to the portal of the container for

enabling the foam producing medicinal composition in said container to be dispensed directly to the desired internal site in the human body by inserting the elongated tube portion into an orifice of the human body, advancing the tube portion into the cavity associated therewith and enabling the foam producing medicinal composition to be dispensed directly to the desired site as a foam mousse in response to pressure is being applied to the thin walled, flexible container.

8. (Original) The delivery system defined in Claim 7, wherein the elongated tube portion comprises an elongated delivery channel formed by the internal diameter thereof which is constructed for controlling the delivery pressure produced by squeezing the flexible container.

9. (Currently Amended) ~~The delivery system defined in Claim 8, wherein the~~  
A delivery system for enabling the dispensing of medicinal compositions directly to an internal site in a human body, said delivery system comprising:

- A. a container
  - a. constructed for receiving and retaining the medicinal compositions therein,
  - b. incorporating an exit portal; and
  - c. a thin-walled, flexible construction;

cr  
A.  
B. closure means mounted to the portal of the container for securely retaining the medicinal composition; and comprising a cap member affixed to the portal of the container for enabling the medicinal composition in said container to be dispensed directly to the desired internal site in the human body by inserting the elongated tube portion into an orifice of the human body, advancing the tube portion into the cavity associated therewith and enabling the medicinal composition to be dispensed directly to the desired site as pressure is applied to the thin walled, flexible container;

C. a delivery nozzle or cannula mounted to the closure means and comprising:

a. an elongated tube portion,

1. having an overall length constructed for ease of insertion into an orifice communicating with a cavity of the human body, said overall length being constructed to assure the complete insertion of the tube portion into the cavity without injuring any surrounding tissue; and

2. an elongated delivery channel formed by the internal diameter which is constructed for controlling the delivery pressure produced by squeezing the flexible container, said internal diameter of said elongated tube portion is being

further defined as ranging between about 0.05 inches and 0.20 inches; and

- b. at least one aperture formed along the distal end of said elongated tube portion for enabling the medicinal composition to be dispensed from the container through the tube portion directly to the desired site.

*ca*  
*A.* 10. (Original) The delivery system defined in Claim 9, wherein the internal diameter of said elongated tube portion is further defined as ranging between about 0.08 inches and 0.156 inches.

11. (Currently Amended) The delivery system defined in Claim ~~2~~ 9, wherein said elongated tube portion is further defined as comprising an overall length ranging between about 2 inches and 3.5 inches.

12. (Original) The delivery system defined in Claim 11, wherein the outer diameter of said elongated tube portion is further defined as ranging between about 0.25 inches and 0.35 inches.

13. (Currently Amended) ~~The~~ A delivery system defined in Claim 7, wherein for enabling the dispensing of a medicinal composition directly to an internal site in a human body, said medicinal composition comprises a therapeutic and anti-viral douche formulation, said delivery system comprising:

A. a container

a. constructed for receiving and retaining the medicinal compositions therein,

b. incorporating an exit portal; and

c. comprising a thin-walled, flexible construction;

B. closure means mounted to the portal of the container for securely retaining the medicinal composition; and comprising a cap member affixed to the portal of the container for enabling the medicinal composition in said container to be dispensed directly to the desired internal site in the human body by inserting the elongated tube portion into an orifice of the human body, advancing the tube portion into the cavity associated therewith and enabling the medicinal composition to be dispensed directly to the desired site as pressure is applied to the thin walled, flexible container;

C. a medicinal composition in the form of a therapeutic and anti-viral douce formulation comprising:

- over*  
*A.*
- a. between about 0.01% and 0.08% by weight based upon the weight of the entire composition of citric acid powder;
  - ~~B~~ b. between about 1% and 5% by weight based upon the weight of the entire composition of one selected from the group consisting of nonoxynol-9 and octoxynol-9;
  - ~~C~~ c. between about 8% and 12% by weight based upon the weight of the entire composition of glycerine;
  - ~~D~~ d. between about 0.30% and 2.0% by weight based upon the weight of the entire composition of povidone iodine; and
  - ~~E~~ e. deionized water forming the balance;

D. a delivery nozzle or cannula mounted to the closure means and comprising:

- a. an elongated tube portion having an overall length constructed for ease of insertion into an orifice communicating with a cavity of the human body, said overall length being constructed to assure the complete insertion of the tube portion into the cavity without injuring any surrounding tissue; and
- b. at least one aperture formed along the distal end of said elongated tube portion for enabling the douche formulation to be dispensed from the container through the tube portion directly to the desired site.



14. (Original) The delivery system defined in Claim 13, wherein said douche formulation is further defined as comprising:

- A. 0.05% by weight based upon the weight of the entire composition of citric acid powder;
- B. 1.00% by weight based upon the weight of the entire composition of one selected from the group consisting of nonoxynol-9 and octoxynol-9;
- C. 10% by weight based upon the weight of the entire composition of glycerine;
- D. 0.03% by weight based on the weight of the entire composition of povidone iodine;
- E. a suitable quantity of a fragrance, as needed; and
- F. deionized water forming the balance.

15. (Canceled)

16. (Currently Amended) ~~The A~~ delivery system defined in Claim 15, wherein ~~said check valve comprises~~ for enabling the dispensing of medicinal compositions directly to an internal site in a human body, said delivery system comprising:

- A. a container constructed for receiving and retaining the medicinal compositions therein and incorporating an exit portal;

- cl*  
*A,*
- B. closure means mounted to the portal of the container for securely retaining the medicinal composition; and
  - C. a delivery nozzle or cannula mounted to the closure means and comprising:
    - A. an elongated tube portion having an overall length constructed for ease of insertion into an orifice communicating with a cavity of the human body, said overall length being constructed to assure the complete insertion of the tube portion into the cavity without injuring any surrounding tissue; and
    - b. at least one aperture formed along the distal end of said elongated tube portion for enabling the medicinal composition to be dispensed from the container through the tube portion directly to the desired site; and
  - D. a check valve mounted in the container for preventing backflow into the container and comprising a cup member mounted in the portal of the container and said cup member comprises:
    - A. a cylindrical shape closed at one end thereof;
    - B. an aperture formed in the closed end;
    - C. a ball member movably mounted in association with the aperture;
    - and

- D. a disk incorporating a plurality of apertures formed therein, said disk being axially movable in said cup member through a limited distance for controlling the movement of the ball member into and out of the aperture.

17. (Original) The delivery system defined in Claim 16, wherein said cup member further comprises an inwardly extending lip formed on an inside surface thereof adjacent the disk for controlling the axial movement of the disk.


18. (New) The delivery system defined in Claim 1, wherein said therapeutic agent comprises at least one selected from the group consisting of silver nitrate solutions, silver nanocrystals, and equivalent compounds.

19. (New) A medicinal delivery system for enabling the application of an antibacterial/antiviral foam producing composition to a topical or internal site of an individual, said delivery system comprising:

- A. an antibacterial/antiviral foam producing composition comprising
  - a. between about 5% and 70% by weight based upon the weight composition of at least one surfactant selected from the group consisting of polysorbate 20, cocamide DEA, polysorbate 60, polysorbate 80, ammonium or alkaline salts of sulfated aliphatic

alcohols, ammonium or alkaline salts of sulfated aliphatic  
ethoxylated alcohols, cocoamido derivatives and ethoxylate  
aliphatic phenolics;

- b. an effective amount of at least one therapeutic agent selected from  
the group consisting of silver nitrate solutions, silver nanocrystals,  
and equivalents thereof, and
- c. water forming the balance; and


- 
- B. a container for dispensing the therapeutic agent as an integral component  
of the foam mousse for direct application of the foam mousse to the skin  
and/or an internal site of an individual, said container comprising one  
selected from the group consisting of finger actuated foam producing  
valve bearing containers and squeeze bottle foam producing containers.

20. (New) An all natural foam mousse producing medicinal composition  
constructed for use on an individual's skin surface and/or internal site, said composition  
comprising

- A. between about 30% and 60% by weight based upon the weight of the  
entire composition of a vegetable oil based soap;
- B. between about 50% and 90% by weight based upon the weight of the  
entire composition of water;
- C. a pH adjusting agent; and

- D. an effective amount of at least one therapeutical agent selected from the group consisting of silver nanocrystals, silver nitrate solutions, and equivalents thereof.

21. (New) The all natural foam mousse producing composition defined in Claim 20, wherein the vegetable oil based soap is further defined as comprising one selected from the group consisting of palm kernel oil and coconut oil.

 22. (New) A method for providing a foam mousse delivery system for producing a foam medicinal mousse for topical and/or internal use by an individual, said method comprising the steps of:

- A. selecting a housing for retaining a product therein;
- B. affixing a finger actuated valve/cap affixed to the housing, said valve/cap being constructed for withdrawing the product from the housing and dispensing the product as a foam mousse; and
- C. placing a product in said container, said product comprising
  - a. between about 5% and 70% by weight based upon the weight composition of at least one surfactant selected from the group consisting of polysorbate 20, cocamide DEA, polysorbate 60, polysorbate 80, ammonium or alkaline salts of sulfated aliphatic alcohols, ammonium or alkaline salts of sulfated aliphatic

ethoxylated alcohols, cocoamido derivatives and ethoxylate aliphatic phenolics;


- b. an effective amount of at least one therapeutic agent selected from the group consisting of silver nitrate solutions, silver nanocrystals, and equivalents thereof, and
- c. water forming the balance.

*cf. A,*  
23. (New) The method defined in Claim 22, wherein said foam producing valve/cap is further defined as being constructed for withdrawing the product stored in the housing and infusing air into the composition to dispense the foam mousse.

24. (New) A method for providing the delivery of a medicinal, anti-bacterial/antiviral foam mousse composition to a desired site of an individual comprising the steps of:

- A. dispensing a medicinal foam mousse from a container housing a medicinal foam producing composition, said composition comprising
  - a. between about 5% and 70% by weight based upon the weight composition of at least one surfactant selected from the group consisting of polysorbate 20, cocamide DEA, polysorbate 60, polysorbate 80, ammonium or alkaline salts of sulfated aliphatic alcohols, ammonium or alkaline salts of sulfated aliphatic

ethoxylated alcohols, cocoamido derivatives and ethoxylate  
aliphatic phenolics;

- 
- b. an effective amount of at least one therapeutic agent selected from  
the group consisting of silver nitrate solutions, silver nanocrystals,  
and equivalents thereof, and
  - c. water forming the balance;

- B. applying the medicinal foam mousse onto the surface of an applicator;
- C. rubbing the medicinal foam mousse bearing applicator on the skin  
surface to be treated; and
- D. rinsing and/or towel drying the treated skin surface;

whereby a substantially enhanced medicinal composition is delivered directly to a  
desired skin surface site.

---